These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25103068)

  • 21. Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers.
    Mavrakanas TA; Lipman ML
    Can J Diabetes; 2018 Apr; 42(2):118-123. PubMed ID: 29602404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to?
    Sindone A; Erlich J; Lee C; Newman H; Suranyi M; Roger SD
    Intern Med J; 2016 Mar; 46(3):364-72. PubMed ID: 26968600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telmisartan, ramipril, or both in patients at high risk of vascular events.
    Büchner N; Banas B; Krämer BK
    N Engl J Med; 2008 Jul; 359(4):426. PubMed ID: 18650521
    [No Abstract]   [Full Text] [Related]  

  • 24. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions.
    Moser M
    J Am Coll Cardiol; 1997 Jun; 29(7):1414-21. PubMed ID: 9180098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationships between Medication Adherence and Cardiovascular Disease Risk Factor Control in Elderly Patients with Diabetes.
    Raebel MA; Dyer W; Nichols GA; Goodrich GK; Schmittdiel JA
    Pharmacotherapy; 2017 Oct; 37(10):1204-1214. PubMed ID: 28752555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Not just numbers, but years of science: putting the ACE inhibitor-ARB meta-analyses into context.
    Ferrari R; Rosano GM
    Int J Cardiol; 2013 Jun; 166(2):286-8. PubMed ID: 23452882
    [No Abstract]   [Full Text] [Related]  

  • 27. Incidence of new stroke or new myocardial infarction or death at 39-month follow up in patients with diabetes mellitus, hypertension, or both treated with and without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Ravipati G; Aronow WS; Ahn C; Alappat RM; McClung JA; Weiss MB
    Am J Ther; 2009; 16(1):2-4. PubMed ID: 19114876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Where does the evidence lead us for the proper use of angiotensin II inhibitors in the management of cardiovascular disease?
    Guthrie RM
    Cardiology; 2010; 117(3):216-8. PubMed ID: 21160183
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
    Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
    J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice.
    Barrios V; Coca A; Escobar C; Enrique R; Rincón LM
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):159-66. PubMed ID: 22292872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The clinical usefulness of RAAS inhibitors in hypertensive patients].
    Yamaguchi K; Sata M
    Nihon Rinsho; 2012 Sep; 70(9):1571-6. PubMed ID: 23012805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications.
    Podar T; Tuomilehto J
    Drugs; 2002; 62(14):2007-12. PubMed ID: 12269846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
    Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
    Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
    Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
    Shih CJ; Chu H; Ou SM; Chen YT
    Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?
    Nehme A; Zibara K
    Hypertens Res; 2017 Nov; 40(11):903-909. PubMed ID: 28680167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
    Böhm M; Baumhäkel M; Mahfoud F; Werner C
    Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R; Boersma E
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ONTARGET still OFF-TARGET?
    Lambers Heerspink HJ; de Zeeuw D
    Circulation; 2011 Mar; 123(10):1049-51. PubMed ID: 21357820
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.